Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Pluri Inc PLUR

Healthcare Biotechnology
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PLUR)

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

GlobeNewswire April 8, 2024

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

GlobeNewswire March 28, 2024

Pluri Inc. Announces 1-for-8 Reverse Share Split

GlobeNewswire March 27, 2024

Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

GlobeNewswire March 21, 2024

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

GlobeNewswire March 19, 2024

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

GlobeNewswire March 14, 2024

Pluri(TM) Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

GlobeNewswire March 11, 2024

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

GlobeNewswire March 6, 2024

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

GlobeNewswire February 28, 2024
View More News ››

Opinion & Analysis (NDAQ:PLUR)

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Streetwise Reports June 18, 2020

Three COVID-19 Patients Treated with PLX Cells

Streetwise Reports April 2, 2020

Companies flocking to Japan for biotech deals

The Life Sciences Report February 2, 2017

How three companies have been resurrected from failed clinical trials:George Zavoico of JonesTrading

The Life Sciences Report April 6, 2016
View More Opinion ››

Bullboard Posts (NDAQ:PLUR)

Excellent YT analysis on PLUR

https://youtu.be/Cr0Cq1H9JPI?si=AdvJfH3Xp7soFT9x
BryceCanada - March 26, 2024

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.”

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company’s Strategy to Leverage its Innovative 3D Cell-based...
lucaM1 - July 27, 2022

Pluristem trial shows accelerated muscle regeneration

Phase III study of allogeneic PLX-PAD cells confirms “regenerative medicine is effective in elderly”. https://longevity.technology...
lucaM1 - July 19, 2022

HC Wainwright Reiterates On Pluristem After Encouraging Init

Yesterday Pluristem Therapeutics Inc (NASDAQ: PSTI) announced top-line results from its Phase 3 trial evaluating...
lucaM1 - July 17, 2022

Pluristem's CEO on today's results

 “While we were disappointed that this significant benefit did not translate to an SPPB score improvement, Pluristem will seek...
lucaM1 - July 13, 2022

A New Food Ecosystem Emerges in Israel

The story of of Pluristem got into cultured meat.  https://www.ift.org/news-and-publications/food-technology-magazine/issues/2022...
lucaM1 - July 10, 2022
View more Bullboard ››

Geologica Resource Corp.

Geologica Resource Corp.

Geologica Resource Corp. is an exploration and development company focused on the acquisition, exploration and development of ...
View More »